ArticlePeerJ2021
The m
Article in PeerJ, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- PCAT6 Regulates IGF2BP1/PD-L1 to Promote Immune Escape in Breast Cancer.The journal of gene medicine · 2026Article
- Identifying the relationship between exosome genes and breast cancer risk using bioinformatics and machine learning methods.Discover oncology · 2026Article
- A risk model based on signature genes predicts prognosis and associates with tumor immunity, drug sensitivity in breast cancer.Cancer biomarkers : section A of Disease markers · 2025Article
- Prognostic significance and identification of m6A regulator genes and hub genes associated with m6A in breast cancer.Discover oncology · 2024Article
- IGF2BPs as novel mGenes & diseases · 2024Review
- The Tumor Stemness Indice mRNAsi can Act as Molecular Typing Tool for Lung Adenocarcinoma.Biochemical genetics · 2023Article
- Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner.International journal of biological sciences · 2023Article
- Integrating single-cell RNA-seq and spatial transcriptomics reveals MDK-NCL dependent immunosuppressive environment in endometrial carcinoma.Frontiers in immunology · 2023Article
- MLSP: A bioinformatics tool for predicting molecular subtypes and prognosis in patients with breast cancer.Computational and structural biotechnology journal · 2022Article
- The emerging roles and mechanism of m6a in breast cancer progression.Frontiers in genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
N6-methyladenosine (m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.